Skip Nav Destination
Issues
1 August 2019
-
Cover Image
Cover Image
ABOUT THE COVER
The Xp11.2 chromosomal translocation underlies a subgroup of aggressive renal cell carcinomas (TFE3-RCC) with distinct molecular and histological features. These tumors are driven by a pathogenic chimeric form of the TFE3 transcription factor, but diagnostic and therapeutic options for TFE3-RCC are limited. Using a novel transgenic mouse model, the authors found that RET kinase expression was upregulated in mouse kidney tumors with chimeric TFE3 signaling, and TFE3-RCC mouse tumors demonstrated a therapeutic response to the RET inhibitor vandetanib. As shown in a representative section on the cover, immunohistochemical staining for RET was also positive in human kidney tumors from patients with TFE3-RCC. Additionally, the authors identified Glycoprotein Nonmetastatic B (GPNMB) as a novel biomarker of TFE3-RCC that outperformed the conventional marker, Cathepsin K. These findings expand the potential diagnostic and therapeutic options for TFE3-RCC, and present a novel mouse model for further preclinical investigation. See the article by Baba et al. on page 1613 for more information. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1541-7786
EISSN 1557-3125
Molecular Cancer Research
Table of Contents
Highlights
Review
Rapid Impact
Prostate Cancer in World Trade Center Responders Demonstrates Evidence of an Inflammatory Cascade
Yixuan Gong; Li Wang; Haocheng Yu; Naomi Alpert; Mitchell D. Cohen; Colette Prophete; Lori Horton; Maureen Sisco; Sung-Hyun Park; Hyun-Wook Lee; Judith Zelikoff; Lung-Chi Chen; Dana Hashim; Mayte Suarez-Farinas; Michael J. Donovan; Stuart A. Aaronson; Matthew Galsky; Jun Zhu; Emanuela Taioli; William K. Oh
Cancer Genes and Networks
Author Choice
TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease
Masaya Baba; Mitsuko Furuya; Takanobu Motoshima; Martin Lang; Shintaro Funasaki; Wenjuan Ma; Hong-Wei Sun; Hisashi Hasumi; Ying Huang; Ikuma Kato; Tsuyoshi Kadomatsu; Yorifumi Satou; Nicole Morris; Baktiar O. Karim; Lilia Ileva; Joseph D. Kalen; Luh Ade Wilan Krisna; Yukiko Hasumi; Aiko Sugiyama; Ryoma Kurahashi; Koshiro Nishimoto; Masafumi Oyama; Yoji Nagashima; Naoto Kuroda; Kimi Araki; Masatoshi Eto; Masahiro Yao; Tomomi Kamba; Toshio Suda; Yuichi Oike; Laura S. Schmidt; W. Marston Linehan
The Codon 72 TP53 Polymorphism Contributes to TSC Tumorigenesis through the Notch–Nodal Axis
Jun-Hung Cho; Bhaumik Patel; Santosh Bonala; Hossein Mansouri; Sasikanth Manne; Surya Kumari Vadrevu; Shanawaz Ghouse; Che-Pei Kung; Maureen E. Murphy; Aristotelis Astrinidis; Elizabeth P. Henske; David J. Kwiatkowski; Maciej M. Markiewski; Magdalena Karbowniczek
Cell Fate Decisions
Genome Maintenance
Metabolism
Signal Transduction and Functional Imaging
Tumor Microenvironment and Immunobiology
T-Cell Deletion of MyD88 Connects IL17 and IκBζ to RAS Oncogenesis
Christophe Cataisson; Rosalba Salcedo; Aleksandra M. Michalowski; Mary Klosterman; Shruti Naik; Luowei Li; Michelle J. Pan; Amalia Sweet; Jin-Qiu Chen; Laurie G. Kostecka; Megan Karwan; Loretta Smith; Ren-Ming Dai; C. Andrew Stewart; Lyudmila Lyakh; Wang-Ting Hsieh; Asra Khan; Howard Yang; Maxwell Lee; Giorgio Trinchieri; Stuart H. Yuspa
Correction
Journal Archive
Molecular Cancer Research
(2002-Present; volumes 1-current)Published monthly since November, 2002.
(ISSN 0008-5472)
Cell Growth & Differentiation
(1990-2002; volumes 1-13)Published monthly 1990- September, 2002.
(ISSN 1044-9523)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.